Celerion Opens Operations in South Korea at Seoul National University Hospital Clinical Trial Center

Celerion is pleased to announce the expansion of clinical operations to South Korea. Through partnership with Seoul National University Hospital (SNUH), the new Asian office is located within the SNUH Clinical Trials Center. This enables Celerion and clients access to the 80-bed clinical research unit, particularly geared toward clinical pharmacology, oncology, and pediatrics, as well as the highly trained staff at this centre. The new Asian office will be overseen by John Horkulak, Executive Director, Eurasian Site Operations. Mr Horkulak brings over 20 years of experience in managing clinical pharmacology studies in patient populations to this role.

The focus of the SNUH Clinical Trials Center is translational medicine and aligns with Celerion’s strategic vision to provide effective global services that support growing interest in complex early clinical studies, often involving patients. In addition, Celerion has built relationships and audited three other clinical trial centres in South Korea to support the need for multi-site early clinical studies in patients often requiring confinement.

“We are very pleased to have a presence in South Korea through our partnership with Seoul National University Hospital,” said Susan Thornton PhD, President and CEO at Celerion. “They are a highly respected institution and among the global leaders in the conduct of quality medical research.”

“The partnership enables us to participate more actively in global drug development programs as well as supporting the early clinical research needs for the emerging Korean drug discovery industry,” said Professor Yung-Jue Bang MD PhD, President of the Biomedical Research Institute at SNUH, who also serves as the Director to the Clinical Trials Center.“